~~<i id='DCA91E2C5A'><strike id='DCA91E2C5A'><tt id='DCA91E2C5A'><pre id='DCA91E2C5A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：focus 2025-09-07 04:09:33 - browse：1182

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： For Medicare Advantage, Democrats want stronger protections around AI

knowledge

hotspot

entertainment

hotspot

entertainment

knowledge

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

WSS

Duchenne breakthrough therapy leaves behind pioneering families

What we’ve learned from the Aduhelm mess

KalVista pill reduced swelling 'attacks' caused by genetic disease

Anesthesiologist group: stop taking Ozempic before surgery

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Gilead might be held responsible for not developing a drug

hotspot

leisure time

knowledge

In Memoriam: Notable people who died in 2023

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cancer drug shortages should be causing more outrage

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Bright Health sells Medicare Advantage business to Molina

Key House Republican on health care plans exit from Congress

Virginia high school admissions case could be legal follow

In Memoriam: Notable people who died in 2023

At least 13 dead in Texas as scorching temps continue

BioAge raises $170M for combination therapy with Zepbound

hotspot

Psychedelics group wrestles with new pharma identity

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Robert F. Kennedy is pitching centrism on health, even on abortion

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

entertainment

hotspot

entertainment

knowledge